Bavarian Nordic A/S BAVA

COP: BAVA | ISIN: DK0015998017   5/05/2025
158,45 DKK (-0,69%)
(-0,69%)   5/05/2025

9 mei 2025 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

9 mei 2025 · Bavarian Nordic Announces Interim Results for the First Three Months of 2025 · Persbericht

6 mei 2025 · Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines · Persbericht

2 mei 2025 · Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom · Persbericht

16 april 2025 · Bavarian Nordic’s Chikungunya Vaccine Receives Recommendation from U.S. CDC’s Advisory Committee on Immunization Practices (ACIP) · Persbericht

9 april 2025 · Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S · Persbericht

9 april 2025 · Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S · Persbericht

31 maart 2025 · Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine · Persbericht

12 maart 2025 · Bavarian Nordic A/S – Notice Convening Annual General Meeting · Persbericht

7 maart 2025 · Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older · Persbericht

5 maart 2025 · Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such · Persbericht

5 maart 2025 · Bavarian Nordic Publishes Annual Report 2024 · Persbericht

28 februari 2025 · Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older · Persbericht

25 februari 2025 · Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine · Persbericht

14 februari 2025 · Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older · Persbericht

3 februari 2025 · Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025 · Persbericht

31 januari 2025 · Bavarian Nordic – Completion of Share Buy-Back Program · Persbericht

31 januari 2025 · Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older · Persbericht

27 januari 2025 · Bavarian Nordic – Transactions in Connection with Share Buy-Back Program · Persbericht

20 januari 2025 · Bavarian Nordic – Transactions in Connection with Share Buy-Back Program · Persbericht

Mijn selecties